New Key Statistics Module, Z-Score and F-Score
NAS:RETA Key Ratios
| Market Cap $ M | 6,566.44 |
| Enterprise Value $ M | 6,402.23 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 74.74 |
| Price/Sales | 303.45 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 23.00 |
| EPS (TTM) $ | -2.98 |
| Beneish M-Score | 34.23 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -30.20 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -136.03 |
| EV-to-EBITDA | -139.38 |
| PEG | -- |
| Shares Outstanding M | 38.10 |
| Net Margin (%) | -373.17 |
| Operating Margin % | -1,455.08 |
| Pre-tax Margin (%) | -373.40 |
| Quick Ratio | 3.19 |
| Current Ratio | 3.21 |
| ROA % (ttm) | -16.31 |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -228.72 |
| Dividend Yield % | -- |
| Altman Z-Score | 5.73 |
RETA Number of Guru Trades
RETA Volume of Guru Trades
Gurus Latest Trades with NAS:RETA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:RETA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Reata Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:RETA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers